Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.
Rollins
Gina
G
D004305:Dose-Response Relationship, Drug; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D017698:Postmenopause / Q000187:drug effects* / Q000502:physiology; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D014549:Urinary Incontinence / Q000188:drug therapy*; D014666:Vasomotor System / Q000187:drug effects*
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride